



(11) **EP 3 911 354 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) International Patent Classification (IPC):
A61K 38/16 ^(2006.01) **A61K 48/00** ^(2006.01)
C07K 14/00 ^(2006.01) **C12N 15/86** ^(2006.01)
A61P 27/16 ^(2006.01)

(48) Corrigendum issued on:
03.04.2024 Bulletin 2024/14

(52) Cooperative Patent Classification (CPC):
A61K 38/16; A01K 67/0275; A01K 67/0276;
A61K 48/005; A61P 27/16; C07K 14/47;
A01K 2217/056; A01K 2217/075; A01K 2217/20;
A01K 2227/105; A01K 2267/0306;
C12N 2750/14143; C12N 2750/14144

(45) Date of publication and mention
of the grant of the patent:
19.07.2023 Bulletin 2023/29

(21) Application number: **20701951.4**

(86) International application number:
PCT/EP2020/051283

(22) Date of filing: **20.01.2020**

(87) International publication number:
WO 2020/148458 (23.07.2020 Gazette 2020/30)

(54) **AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENE**

AAV-VERMITTELTE GENTHERAPIE ZUR WIEDERHERSTELLUNG DES OTOFERLIN-GENS
THÉRAPIE GÉNIQUE MÉDIÉE PAR AAV RESTAURANT LE GÈNE OTOFERLINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

• **PETIT, Christine**
75012 Paris (FR)

(30) Priority: **18.01.2019 EP 19305071**

(74) Representative: **Icosa**
83 avenue Denfert-Rochereau
75014 Paris (FR)

(43) Date of publication of application:
24.11.2021 Bulletin 2021/47

(56) References cited:
• **HANAN AL-MOYED ET AL: "A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice", EMBO MOLECULAR MEDICINE (ONLINE), vol. 11, no. 1, 1 January 2019 (2019-01-01), page e9396, XP055574125, DE ISSN: 1757-4684, DOI: 10.15252/emmm.201809396**
• **AHMED HENA ET AL: "Emerging Gene Therapies for Genetic Hearing Loss", JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY, SPRINGER, NEW YORK, NY, US, vol. 18, no. 5, 16 August 2017 (2017-08-16), pages 649-670, XP036327909, ISSN: 1525-3961, DOI: 10.1007/S10162-017-0634-8 [retrieved on 2017-08-16]**

(60) Divisional application:
23184106.5 / 4 295 913

(73) Proprietors:
• **Institut Pasteur**
75015 Paris (FR)
• **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)**
75016 Paris (FR)
• **INSERM (Institut National de la Santé et de la Recherche Médicale)**
75013 Paris (FR)

(72) Inventors:
• **SAFIEDDINE, Saaid**
75012 Paris (FR)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 911 354 B8